Free shipping on all orders over $ 500

CDK Cyclin-dependent kinase

Cat.No.  Name Information
M1806 PD 0332991 HCL PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.
M1974 Roscovitine (Seliciclib) Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
M2112 LY2835219 mesylate LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
M1807 SCH727965 (dinaciclib) SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively.
M3519 PHA-848125 PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.
M5228 THZ1 THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.
M1710 Flavopiridol Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively.
M6167 Palbociclib Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases.
M5305 RO-3306 RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
M4889 Ribociclib succinate (LEE011 succinate) Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
M9553 PF-06873600 PF-06873600 is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
M9489 SY-1365 SY-1365 (Mevociclib) is a potent, first-in-class, selective CDK7 inhibitor with a Ki value of 17.4 nM.Mevociclib exhibits antiproliferative and apoptotic activity in solid tumor cell lines.
M8995 THZ2 THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM).
M8969 LY-3177833 LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM.
M8962 Voruciclib Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively.
M8902 CVT-313 CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro.
M8497 NU6140 NU6140 is a CDK2 inhibitor with 10-36-fold selectivity over other CDK family members.
M8369 PNU112455A hydrochloride PNU112455A is an ATP site competetive inhibitor of CDK2 and CDK5.
M8015 Purvalanol A Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor.
M7557 ON123300 ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8.
M6589 CGP 60474 CGP60474 is a highly effective anti-endotoxin drug, It is an effective cyclin-dependent kinase (CDK) inhibitor (IC50 of CDK1/B, CDK2/E, CDK2/ A, CDK4/D, CDK5/ P25, CDK7/H and CDK9/T are 26, 3, 4, 216, 10, 200 and 13 nM, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor.
M6283 SCH 900776 (CAS:891494-64-7) MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2.
M6199 MSC2530818 MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.
M6160 Bohemine Bohemine is A selective CDK inhibitor with IC50 of 4.6 μM, 83 μM and 2.7 μM against Cdk2/ Cyclin E, Cdk2/ Cyclin A and Cdk9/cyclin T1, respectively. Bohemine also inhibited ERK2, IC50 was 52 μM, and inhibited CDK1, CDK4 and CDK6. Bohemine is also a purine analogue and has a wide range of anticancer activities.
M5332 NU2058 NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.
M5328 LDC000067 LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
M5263 LDC4297 LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs).
M5029 WHI-P180 Whi-p180 (Janex 3) is a multikinase inhibitor; The IC50 values of RET, KDR and EGFR were 5 nM, 66 nM and 4 μM, respectively.
M4617 Cucurbitacin-E Cucurbitacin-E is a natural compound which from the climbing stem of Cucumic melo L, which significantly suppresses the activity of the cyclin B1/CDC2 complex.
M4460 Oroxylin-A Oroxylin A is an active flavonoid that inhibits the phosphorylation of MDM2 and SIRT1 through the inhibition of CDK9, thus inhibiting MDM2-mediated degradation of P53 and SIRT1-mediated deacetylation of P53, and ultimately stabilizing the P53 protein.Oroxylin A has strong anticancer activity.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.